CAR T cells for acute myeloid leukemia: The LeY of the land

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 1983-1984

  Brenner, Malcolm K ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; LEY ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CELL EXPANSION; CELL MIGRATION; CELL THERAPY; CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; CYTOKINE STORM; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; NEUTROPENIA; NOTE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; TRANSGENE;

FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, MYELOID, ACUTE; LEWIS BLOOD-GROUP SYSTEM; MALE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84887491539     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.234     Document Type: Note

References (12)

1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. (2013). CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra38.
2. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368: 1509-1518.
3. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I et al. (2012). B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
4. Ritchie, DS, Neeson, PJ, Khot, A, Peinert, S, Tai, T, Tainton, K et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21: 2122-2129.
5. Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A and O'Reilly RJ (2012). Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. Blood 120: 1633-1646.
6. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T et al. (2013). Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 5: 176ra33.
7. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J et al. (2011). An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 117: 4262-4272.
8. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
9. Ramos, CA and Dotti, G (2011). Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 11: 855-873.
10. Bonini C, Brenner MK, Heslop HE and Morgan RA (2011). Genetic modification of T cells. Biol Blood Marrow Transplant 17 (1 suppl.): S15-S20.
11. Riley JL (2013). Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med 369: 187-189.
12. Di Stasi A., Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.